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T cellsThe GDP exchange factor (GEF) Vav1 is a central signal transducer downstream of the T cell receptor and has
been identiﬁed as a key factor for T cell activation in the context of allograft rejection. Vav1 has been shown
to transduce signals both dependent and independent of its GEF function. The most promising approach to
disrupt Vav1 activity by pharmacological inhibition would be to target its GEF function. However, the contri-
bution of Vav1 GEF activity for allogeneic T cell activation has not been clariﬁed yet. To address this question,
we used knock-in mice bearing a mutated Vav1 with disrupted GEF activity but intact GEF-independent func-
tions. T cells from these mice showed strongly reduced proliferation and activation in response to allogeneic
stimulation. Furthermore, lack of Vav1 GEF activity strongly abrogated the in vivo expansion of T cells in a
systemic graft-versus-host model. In a cardiac transplantation model, mice with disrupted Vav1 GEF activity
show prolonged allograft survival. These ﬁndings demonstrate a strong requirement for Vav1 GEF activity for
allogeneic T cell activation and graft rejection suggesting that disruption of Vav1 GEF activity alone is sufﬁ-
cient to induce signiﬁcant immunosuppression.
© 2012 Elsevier B.V. Open access under CC BY license.1. Introduction
Since the introduction of potent immunosuppressants such as cal-
cineurin inhibitors and improved immunological matching, the risk of
acute transplant rejection has been reduced considerably. However,
despite a wide range of immunosuppressive agents, severe episodes
of rejection still occur and chronic allograft rejection still poses a sig-
niﬁcant problem [1,2]. In view of both the nonimmune toxicities and
the immunodeﬁciency complications caused by prolonged immuno-
suppression, there is a strong need to develop more speciﬁc immuno-
suppressive therapies [3,4].
T cells are central players in the process of transplant rejection and
are involved both in the acute and chronic rejection phases, present-
ing an important target for immunosuppressive drugs. They drive
graft rejection by direct and indirect mechanisms including apoptosis
induction by cytotoxic T cells, cytokine release by T helper cells and
by promoting T-dependent alloantibody responses [1]. Activation of
allograft-speciﬁc T cells is induced by antigen presenting cells such
as dendritic cells from both the donor and the host. Binding of
MHC–allopeptide complexes to the T cell receptor together with con-
current costimulation triggers intracellular signal cascades leading to
the activation and expansion of alloreactive T cells [5].+41 61 6963373.
aubert),
 license.The members of the Vav family of guanine nucleotide exchange
factors (GEFs) are central signaling molecules downstream of antigen
receptors, and their deﬁciency severely affects antigen receptor sig-
naling, lymphocyte development, activation and proliferation [6].
While Vav2 and Vav3 show a broad expression, Vav1 is primarily
expressed in hematopoietic cells. Upon T cell receptor (TCR) engage-
ment, Vav1 is phosphorylated and recruited to a TCR-proximal signal-
ing complex including LAT, SLP76, GADS and phospholipase C γ1
(PLCγ1). Vav1 has been shown to integrate various different signal
transduction pathways downstream of the TCR and costimulatory re-
ceptors leading to gene expression, cytoskeletal reorganization and
proliferation [7]. Mice deﬁcient for Vav1 show defects in thymic
T cell development and activation of peripheral T cells [8]. T cells lack-
ing Vav1 show reduced Ca2+ﬂux, defective activation of extracellular
signal-regulated kinase (ERK), Protein kinase C (PKC), the serine–
threonine kinase Akt and T cell-APC conjugate formation [9–13].
Vav proteins contain a Dbl homology (DH) domain, which togeth-
er with the adjacent plekstrin homology (PH) and C1 domains confers
GEF activity toward the Rho-family GTPases Rac, Cdc42 and RhoA [14]
[15]. In addition, they contain SH2 and SH3 domains which may me-
diate the GEF-independent functions of Vav. Phosphorylation of regu-
latory tyrosines in the acidic domain relieves the autoinhibitory
interactions resulting in formation of the open, active conformation
and activation of its GEF activity [16,17]. The relative contribution of
the GEF-dependent and GEF-independent function of Vav1 for T cell
signal transduction and activation still remains unclear. Conditional
deletion of Rac1 and Rac2 resulted in a developmental block at the
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In addition, impaired T cell development in Vav1-deﬁcient mice can
be rescued by overexpression of constitutively active Rac1, indicating
that Vav1 transduces pre-TCR signals via Rac1 [19]. The recent devel-
opment of knock-in mice carrying a GEF-deﬁcient Vav1 mutant
(L334A, K335A, Vav1AA/AA) allowed to distinguish between GEF-
dependent and -independent effects in primary cells for the ﬁrst
time. Analysis of these mice showed that the GEF activity of Vav1 is
required for thymic development of T cells and some but not all signal
transduction events like activation of Akt and integrin activation. Im-
portantly, despite being dispensable for Ca2+ ﬂux and ERK activation,
the GEF activity of Vav1 is required for T cell activation and prolifera-
tion [20].
As a central player in T cell activation, Vav1 has been linked to sev-
eral immune-mediated diseases including common variable immu-
nodeﬁciency syndrome and multiple sclerosis [21,22]. We have
previously shown an important role for Vav1 in alloreactive T cell re-
sponses and transplant rejection in a cardiac allograft transplantation
model, demonstrating the immunosuppressive potential of Vav1 in-
hibition [23]. Targeting Vav1 activity by small molecules is difﬁcult
due to its several functions fulﬁlled by distinct domains. Blocking
Vav1 adapter functions, which comprise multiple protein–proteinCD3
CFSE
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Fig. 1. Vav1 GEF function affects T cell proliferation and activation. Puriﬁed T cells from WT o
antibodywith or without soluble anti-CD28 antibody (1 μg/ml). After 72 h, percentage of cells t
by staining for surface CD25 (A). IL-2 secretion in the supernatant of cells stimulated with anti
viation (SD).interactions over large areas is difﬁcult using small molecular weight
inhibitors. Thus trying to disrupt the interactions between Vav1 and
the downstream GTPases and hence its GEF function seems to be
the more feasible approach. However, it is not clear if disruption of
Vav1 GEF function alone is sufﬁcient to induce immunosuppression.
To address this question, we have used the GEF-deﬁcient Vav1AA/AA
mice to analyze the contribution of Vav1 GEF function to allogeneic
T cell activation and transplant rejection. We show that the GEF func-
tion is required for allogeneic T cell activation and proliferation both
in vitro and in vivo. Vav1AA/AA mice show prolonged allograft survival
in the cardiac transplantation model indicating an important role for
Vav1 GEF function in transplant rejection.
2. Material and methods
2.1. Mice
Mutant C57BL/6 mice carrying the GEF-inactivating mutation
L334A/K335A in the Vav1 gene (Vav1AA/AA) along with wild-type
(WT) littermates have been described previously [20]. Animals were
used between 8 and 12 weeks of age. Vav1AA/AA or C57BL/6 WT fe-
male control mice were used as recipients of fully MHC-mismatchedCD3+CD28
r Vav1AA/AA mice were seeded on plates coated with different concentrations of anti-CD3
hat had divided at least oncewasmeasured by CFSE dilution, and activationwasmeasured
-CD3 and anti-CD28 was measured by ELISA (B). Data are shown as mean±standard de-
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grafts. For the systemic graft-versus-host reactivity (GvH) model, fe-
male C.B-17 severe combined immune deﬁciency (SCID)-beige mice
were supplied by Taconic, Bomholt Denmark and kept under speciﬁc
pathogen-free (SPF) conditions. Mice were kept under conventional
conditions in accordance with Swiss federal law and the NIH Princi-
ples of Laboratory Animal Care.2.2. Antibodies and reagents
Fluorochrome-conjugated antibodies for FACS analysis against
mouse CD4, CD8, CD25, IgM and IgG were purchased from BD Phar-
mingen and eBioscience. Antibodies for stimulation against CD3
(hamster anti-mouse CD3ε, 2C11) and CD28 (hamster anti-mouse
CD28, 37.51) were obtained from BD Pharmingen.2.3. T cell proliferation and activation
T cells from spleens and lymph nodes from Vav1AA/AA and C57BL/6
WTmice were puriﬁed by negative selection using the EasySep T cell en-
richment kit according tomanufacturer's instructions (Stemcell Technol-
ogies, Vancouver, CA). Cells were labeled with 5 μM carboxyﬂuorescein
diacetate succinimidyl ester (CFSE) for 10 min at 37 °C. 105 cells were
cultured in the absence or presence of plate-bound antibodies against
CD3 and CD28 (1 μg/ml) for 72 h. Cells were stained with antibodies
against CD4, CD8 and CD25 and analyzed by FACS in duplicates.2.4. Mixed lymphocyte reaction (MLR)
T cells from spleens and lymph nodes from Vav1AA/AA and C57BL/6
WT mice were puriﬁed as described for the T cell activation analysis.
The one-way MLR was performed in 96-well plates using irradiated
BALB/c splenocytes as allogeneic stimulators. Different numbers of puri-
ﬁed responder T cells (1×105, 2×105, 4×105) were mixed with differ-
ent numbers of stimulator splenocytes (2×105, 4×105, 8×105) and
incubated for 4 days at 37 °C in a humidiﬁed incubator. After a 5 hour
exposure to 3H thymidine, proliferation was measured in a Betaplate
Counter (Wallac). Data are shown as mean values±SD of triplicates.Fig. 2. Allogeneic T cell proliferation is reduced in Vav1AA/AA mice in a one-way mixed
lymphocyte reaction. Different amounts of puriﬁed T cells from WT, Vav1AA/AA (A) or
Vav1−/− (B) mice were co-cultured with fully MHC-mismatched irradiated BALB/c
splenocytes for 4 days. Proliferation of allogeneic T cells was measured by thymidine
incorporation. Values are shown as mean±SD (*pb0.05, **pb0.01).2.5. Systemic graft-versus-host (GvH) model
Single cell suspensions were prepared from spleens of Vav1AA/AA
mice and WT littermate controls. After red blood cell lysis with ACK
buffer (Sigma-Aldrich), cells were labeled with 2 μM carboxyﬂuores-
cein diacetate succinimidyl ester (CFSE) for 10 min at 37 °C. SCID-
beige recipient mice were injected i.v. with 20×106 unfractionated
WT splenocytes or 40–60×106 spleen cells from Vav1AA/AA donors,
respectively, to transfer 7×106 T cells (as determined by anti-CD3
staining). Four days after transfer, cell suspensions were prepared
from individual SCID recipient spleens and T-cell recovery was
analyzed by four-color ﬂow cytometry, CFSE, anti-CD4-PE, anti-CD8-
PerCP and anti CD3-APC. Flow cytometry data were acquired on a
FACScalibur (BD Biosciences) using CellQuest software. Data were an-
alyzed with FlowJo software (Treestar, San Carlos, CA, USA). Esti-
mates of CD4+ and CD8+ T-cell numbers per recipient spleen were
calculated as the product of the total number of viable spleen cells
(hemocytometer count, trypan blue exclusion) and the percentage
of CD3+ CD4+ and CD3+ CD8+ spleen cells within the live lympho-
cyte forward/side scatter gate. The percentage of CD4+ or CD8+ T
cells that had undergone a certain number of cell cycles was derived
from marker settings on CFSE histograms. For cell cycle distribution
plots, the arithmetic means and SD of all individual data per recipient
group are shown.2.6. Cardiac allotransplantation
Heterotopic heart transplantation was performed as described by
[24] using aseptic surgery techniques. Brieﬂy, animals were anesthe-
tized using isoﬂurane. Following heparinization of the donor mouse,
the chest was opened and the heart rapidly cooled with ice cold sa-
line. The aorta and pulmonary artery were ligated and divided and
the donor heart was stored in ice cold saline. The recipient was pre-
pared by dissection and cross-clamping of the infra-renal abdominal
aorta and vena cava. The graft was implanted with end-to-side anas-
tomoses between the donor right brachiocephalic trunk and the re-
cipient aorta and the donor right pulmonary artery to the recipient
vena cava. Grafts were monitored by daily palpation and were con-
sidered rejected upon cessation of palpable ventricular contractions.
Genotypes of all animals have been conﬁrmed at the end of the
study.
2.7. Histopathology and immunohistochemistry
Cardiac allografts and recipient hearts were cut transversally and
ﬁxed in 4% buffered formalin for histological evaluation. Fixed tissues
were processed and embedded in parafﬁn according to standard pro-
cedures. Sections were stained with hematoxylin and eosin and Van
Gieson for elastic ﬁbers for light microscopic examination. Acute re-
jections were graded on scale 0 R (no rejection) to 3 R (severe acute
cellular rejection) [25].
Cardiac allografts were analyzed immunohistochemically. Stan-
dard procedures were applied using mAbs anti-alpha smooth muscle
215D. Haubert et al. / Transplant Immunology 26 (2012) 212–219actin (αSMA, clone 1A4, Dako-Cytomation, Glostrup, Denmark), anti-
CD3 (clone CD3-12, Serotec Ltd, Oxford, UK), anti-CD45R (clone RA3-
6B2, Serotec Ltd) and the streptavidin–biotin–peroxidase complex
technique. Spleen tissue served as positive control sample. Negative
immunohistochemical staining controls were obtained by replacing
the primary antibodies with antibody isotype controls (Zymed Labo-
ratories, Inc., San Francisco, CA, USA).2.8. Alloantibody analysis
Puriﬁed CD4+ T cells from BALB/c spleens were incubated with
serum from naive or transplanted wildtype or Vav1AA/AA mice for
30 min on ice. Alloreactive antibodies were detected by FACS using
FITC-conjugated anti-IgM and anti-IgG antibodies.A
B
CD4+total cells
CD4+
***
**
*
n.s.
Fig. 3. Vav1 GEF function affects allogeneic T cell proliferation in a systemic GvH model. CFS
mismatched SCID/beige mice. As a control, additional mice receiving WT splenocytes were t
cell numbers and CFSE dilution. A, total cellularity in recipient spleens after transfer. B,C, p
undergone the indicated number of divisions (n=4 per group). Values are shown as mean2.9. ELISA
Secreted levels of IL-2 in supernatants from stimulated cells were
analyzed by ELISA according to manufacturer's instructions (DuoSet
ELISA kit, R&D Systems, Minneapolis, MN, USA). Absorbance at
450 nm was measured using a SpectraMAX 190 ELISA reader (Molec-
ular Devices).
2.10. Statistical analysis
Data were expressed as mean±standard deviation (SD). Statisti-
cal signiﬁcance was determined using a two-tailed, unpaired Stu-
dent's T-test. (*pb0.05, **pb0.01, n.s. not signiﬁcant). For the heart
allograft transplantation model, signiﬁcance was determined by
Kaplan–Meier survival curves and Mantel–Cox test.C
CD8+
*
n.s.
n.s.
n.s.
n.s.
CD8+
E-labeled donor splenocytes from WT or Vav1AA/AA mice were injected into fully MHC-
reated with CsA. Four days after transfer, proliferation of donor T cells was assessed by
roliferation of CD4+ (B) or CD8+ (C) T cells shown as percentage of cells which have
±SD. Signiﬁcance vs. wild-type values is shown (*pb0.05, **pb0.01).
Recipient of Balb/c heart Individual graft survival (days) Median survival time 
(days)
WT 7,7,7,7,7,7,7,7,7 7
Vav1AA/AA 10,14,18,20,22,23,29,44,>100 22 (**)
A
B
** p < 0.001
Fig. 4. Vav1AA/AA mice show prolonged allograft survival in a cardiac transplantation
model. BALB/c cardiac allografts were transplanted onto WT or Vav1AA/AA recipients
in a C57BL/6 background. Graft beating was identiﬁed by palpation and used to mea-
sure graft survival. A, individual graft survival. B, percentage of mice with beating grafts
shown as Kaplan–Meier survival curve.
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3.1. Disruption of Vav1 GEF function affects T cell proliferation and activation
To address the contribution of the GEF function of Vav1 for T cell activation in the
context of allograft rejection, we made use of knock-in mice which carry a mutation in
the DH domain of Vav1 (Vav1AA/AA). These mice express a mutated Vav1 which cannot
activate Rac but has intact GEF-independent functions such as TCR-induced Ca2+ ﬂux
[20]. In order to determine if disruption of Vav1 GEF activity alone affects T cell prolif-
eration and activation, puriﬁed T cells from Vav1AA/AA and wild-type (WT) control
mice were labeled with the ﬂuorescent dye CFSE and stimulated on plates coated
with antibodies against CD3 and CD28. After 3 days, proliferation and activation were
assessed by ﬂow cytometry. T cells from Vav1AA/AA mice showed impaired proliferation
compared to T cells from WT mice with both TCR stimulation and costimulation by
CD28 (Fig. 1A), in line with previously published results [20]. Activation of Vav1AA/AA
T cells as measured by surface expression of CD25 was also impaired compared to
WT T cells, although they reached almost WT levels of surface CD25 under strong stim-
ulatory conditions. In addition, IL-2 secretion was severely reduced in Vav1AA/AA T cells,
which might contribute to the impaired proliferative potential (Fig. 1B).
As T cell proliferation and activation by antibody-mediated stimulation is affected by the
loss of Vav1GEF activity,wewanted to know if Vav1GEF activity also affects allogeneic T cell
proliferation. To address this question, we cultured equal numbers of puriﬁed T cells of
Vav1AA/AAmice orWT control animalswith irradiated splenocytes from fullymismatched al-
logeneic BALB/c mice in a one-way mixed lymphocyte reaction (MLR). Whereas WT T cells
proliferated strongly in response to increasing numbers of stimulator cells, Vav1AA/AA T cells
showed amarked impairment of proliferation in response to allogeneic stimulation (Fig. 2A).
To compare this phenotype to total Vav1 deﬁciency, we used T cells from Vav1−/−mice in
theMLR. T cells fromVav1−/−mice also showed a strongproliferative defect as observed be-
fore (Fig. 2B) [23], which, despite the total Vav1 deﬁciency, is only slightly stronger com-
pared to Vav1AA/AA T cell. These results indicate that the GEF function of Vav1 has a key
role in the proliferation and activation of allogeneic T cells.
3.2. Vav1 GEF activity is required for full allogeneic T cell expansion in vivo
To test whether the observed proliferation defect of Vav1AA/AA T cells in vitro trans-
lates into an in vivo situation, we used splenocytes from Vav1AA/AA or WTmice in a sys-
temic graft-versus-host (GvH) model. CFSE-labeled splenocytes from Vav1AA/AA or
control mice were injected into BALB/c SCID mice, and alloantigen-driven proliferation
of donor T cells in the recipient spleen was measured after 4 days. To account for the
reduced number of single-positive T cells in Vav1AA/AA mice which is caused by a devel-
opmental defect in the thymus [20], the number of injected splenocytes was increased
accordingly to achieve equal number of injected T cells for the Vav1AA/AA and WT
groups. In addition, a third group treated with cyclosporine A (CsA) was included as
a control for strong immunosuppression. In mice treated with CsA, the number of
total splenocytes as well as CD4+ and CD8+ T cells in the spleen was reduced after
4 days compared to control mice. Interestingly, an almost equally pronounced reduc-
tion in splenocytes and T cells from Vav1AA/AA mice was observed (Fig. 3A). To examine
the proliferation of allogeneic T cells in more detail, the number of cell divisions was
analyzed for CD4+ and CD8+ T cells by CFSE dilution. In contrast to the control mice,
where most of the cells underwent 7 or more division cycles, around 18% of CD4+ T
cells from Vav1AA/AA donor mice did not divide at all, and fewer cells reached 8 division
cycles (Fig. 3B). This impaired proliferation was also seen with CD8+ T cells, although
not as pronounced. Treatment with CsA strongly affected proliferation, leading to more
than 40% of CD4+ T cells that did not proliferate. Although T cells from Vav1AA/AA mice
showed an intermediate proliferative impairment compared to strong immunosuppres-
sive conditions like CsA, these results suggest that Vav1 GEF activity is important for full
allogeneic T cell expansion in the systemic GvH model.
3.3. Prolonged heart allograft survival in mice with disrupted Vav1 GEF activity
We have observed that T cells with disrupted Vav1 GEF activity are impaired in
allogeneic-driven proliferation and activation. To assess if this defect translates into
an in vivo disease situation, we used WT and Vav1AA/AA mice in a heart transplantation
model. Allogeneic heart allografts from BALB/c donors were transplanted into WT or
Vav1AA/AA C57BL/6 recipients. All WT mice readily rejected the allograft after 7 days,
whereas cardiac allograft survival in Vav1AA/AA mice was signiﬁcantly prolonged with
a mean survival time (MST) of 22 days (Fig. 4). The majority of the animals rejected
the allograft after 2–3 weeks, but two mice showed prolonged allograft protection of
more than 3 months, with one animal reaching day 100 post-transplantation.
Analysis of the alloantibody response against the graft showed a strong presence of
IgM and IgG alloantibodies in transplanted WT animals at the day of rejection (Fig. 5).
Vav1AA/AA animals showed almost no increased alloantibody levels at the day of rejec-
tion, including those animals that showed only shortly prolonged graft survival. In ad-
dition, no alloantibody formation could be detected during the graft survival period at
day 28, indicating that antibody-mediated rejection is severely compromised in
Vav1AA/AA mice.
3.4. Histopathology of cardiac allografts in mice with disrupted GEF-activity versus WT mice
In the WT mice the donor hearts showed acute cellular rejection (grade 3 R) with
signs of endothelialitis present. Part of the donor hearts showeddiffuse, severemyocardialnecrosis, most likely ischemic and partially mixed with autolysis. No signs of rejection
were found in syngeneic transplants.
Cardiac allografts of Vav1AA/AA mice also revealed areas of acute cellular rejection
(grade 3 R) (Fig. 6). Myocardial necrosis was present but appeared not to be as diffuse
as in WT mice. In contrast to WT mice, additionally multifocal areas of ﬁbrosis were
present in allografts transplanted into Vav1AA/AA mice. This corresponds to a scattered
progression to a chronic stage, which is supported by the observed prolonged allograft
survival. Endothelialitis was present and single vessels showed a mild chronic vasculo-
pathy. Immunohistochemical examination revealed interstitial cellular rejection com-
posed of mainly T cells mixed with B cells, and a transplant vasculopathy with
αSMA+ cells and T cells for both WT and Vav1AA/AA mice (data not shown).4. Discussion
Vav1 is a central molecule downstream of the TCR and has been
recognized as a key mediator of T cell activation. We have previously
shown that complete deﬁciency of Vav1 inhibits T cell activation lead-
ing to prolonged allograft survival in a transplantation model [23].
However, the relative contribution of the Vav1 GEF activity to its
function in T cell activation in a disease setting has not been
addressed. By using knock-in mice carrying a GEF-inactivating muta-
tion in the Vav1 gene, we demonstrate that Vav1 GEF activity is es-
sential for full T cell activation and proliferation by allogeneic
stimulation. Disruption of only the GEF activity of Vav1, while leaving
the adapter functions intact, leads to signiﬁcantly prolonged allograft
survival in a heart transplantation model. Our ﬁndings reveal a strong
contribution of Vav1 GEF activity to allogeneic T cell activation, indi-
cating that disruption of Vav1 GEF activity by therapeutic agents
may be a novel way to induce immunosuppression.
Vav1 has been shown to participate in the activation of many sig-
nal transduction pathways downstream of the TCR, but which of
these requires Vav1 GEF activity could only recently be addressed in
primary cells [20]. It could be shown that some pathways such as
TCR-induced Ca2+ ﬂux and ERK activation are GEF-independent,
whereas activation of others like the PI3K pathway requires Vav1
GEF activity. Still, T cell proliferation and activation after TCR stimula-
tion are severely suppressed when Vav1 GEF activity is disrupted
(Fig. 1) [20]. Only at very high concentrations of stimulating CD3 an-
tibody and in the presence of costimulation by CD28, the requirement
for Vav1 GEF activity is bypassed. Interestingly, proliferation and acti-
vation of T cells from Vav1AA/AA mice are reduced to the same extent
AB
IgM-FITC
IgM
WT
IgG
IgG-FITC
** ** *
**
Vav1AA/AA
baseline
Tx
d28
Fig. 5. Reduced alloantibody response in Vav1AA/AA mice. Serum fromWT or Vav1AA/AA mice was taken before transplantation (baseline), at the day of rejection (Tx) or during pro-
longed allograft survival at day 28 (Vav1AA/AA only). Alloantibody levels against BALB/c alloantigens were determined by FACS and compared to baseline levels of naive mice. A,
example of alloantibody levels in transplanted WT or Vav1AA/AA mice at day 28 (dotted line), at day of rejection (solid line) compared to baseline levels (shaded). B, summary
of antibody levels in all mice (n=6 (Vav1AA/AA) n=7 (WT)) at day of rejection (Tx) or at day 28 (d28). Data are shown as mean±SD. Signiﬁcance vs. WT Tx is shown
(*pb0.05, **pb0.01).
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essential for this response [20]. A similar effect could be observed
when T cells were stimulated by allogeneic splenocytes in a mixed
lymphocyte reaction, where T cells derived from Vav1AA/AA mice
showed a strongly reduced proliferation almost as strong as T cells
completely lacking Vav1 (Fig. 2). This is surprising, as T cells from
Vav1AA/AA mice have intact Ca2+ and ERK signaling, which is im-
paired in Vav1−/− T cells [10,11]. However, one reason may be that
the defects observed in Vav1−/− T cells are only partial. Deﬁciency
of all three Vav family members completely abolishes these signaling
events, suggesting a redundant function for the other Vav proteins
which could partially compensate Vav1 deﬁciency [26]. In addition,
Vav1 has been shown to promote cell cycle progression via the PI3K
pathway, which is defective in both T cells from Vav1−/− and
Vav1AA/AA mice [20,27]. Furthermore, an important step in T cell acti-
vation, especially in the context of allogeneic stimulation, is the for-
mation of the antigen presenting cell (APC)-T cell conjugate anddownstream actin polymerization events. Vav1 transduces signals
necessary for the activation of integrins important for APC–T cell con-
jugate formation, a function dependent on the GEF activity of Vav1
[12,13,20]. These pathways may explain the strong requirement for
Vav1 GEF activity in allogeneic T cell activation.
T cells from Vav1AA/AA mice also show a proliferative defect when
injected into MHC-mismatched recipient animals in a mechanistic
GvH mouse model (Fig. 3). The total number of Vav1AA/AA T cells
after 3 days was strongly reduced compared to WT T cells, and 18%
of the cells did not divide at all. Interestingly, the majority of
Vav1AA/AA T cells reached 6 division cycles, showing that there was
no complete block in proliferation. Rather, Vav1AA/AA T cells seemed
to have divided more slowly compared to WT T cells, which led to
the reduced total numbers of cells. This is in contrast to T cells treated
with the strong immunosuppressant CsA, where the majority of T
cells did not divide at all. However, in a previous study, T cells from
Vav1−/− mice also did not show a complete block in proliferation
Fig. 6. Histopathology of BALB/c cardiac allografts in Vav1AA/AA C57BL/6mice. A, graft show-
ing interstitial ﬁbrosis within the myocardium with mononuclear cellular inﬁltrates and
mild hemorrhages (100 day survival). B, graft showing blood vessel with endothelialitis,
perivascular mononuclear cellular inﬁltrates, hemorrhage and edema (44 day survival).
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from mice deﬁcient in both Vav1 and Vav2 [23]. These ﬁndings sug-
gest that disruption of Vav1 function only partially affects the TCR-
induced proliferative signals which can be overcome by a stronger
costimulatory environment in vivo. Vav1 GEF activity seems to be im-
portant for the Vav1-mediated proliferative response, as Vav1 GEF in-
activation and total Vav1 deﬁciency have comparable effects. CsA,
however, might affect Vav-independent TCR-induced signals and
also different stimuli in addition to TCR engagement such as cytokines
and costimulatory signals, which also contribute to T cell proliferation
[28]. Furthermore, CsA has effects on other cell types and tissues
resulting in strong general immunosuppression, which may explain
the stronger response compared to Vav1 inactivation.
Vav1AA/AA mice show prolonged cardiac allograft survival with a
mean survival time of 22 days compared to WT animals which reject
the allograft after 7 days (Fig. 4). These ﬁndings conﬁrm the previous-
ly observed central role for Vav1 in allograft rejection [23]. Vav1AA/AA
as well as Vav1−/− mice have reduced numbers of peripheral T cells
due to a defect in thymic development [20], and we cannot exclude
a partial effect of this reduction on allograft survival. However,
Vav1AA/AA T cells showed a strong defect in allogeneic T cell prolifer-
ation and activation in vitro and in vivo when equal numbers of T
cells were used, indicating that the prolonged allograft survival in
Vav1AA/AA mice is likely to be caused by defective T cell activation.However, to fully conﬁrm these ﬁndings, inducible genetic systems
or speciﬁc Vav1 inhibitors will be needed.
Graft survival in Vav1AA/AA mice is not as pronounced as in Vav1−/−
mice which lack the whole Vav1 protein, indicating that the GEF func-
tion of Vav1 affects only part of the processes mediating rejection
[23]. This could also account for the high variation in allograft survival
time observed for the Vav1AA/AA mice. A similar effect has been ob-
served in a study where disruption of Vav1-induced Rac activation by
pharmacological interference resulted only in moderately prolonged
cardiac allograft survival [29]. Histological examination showed signs
of acute cellular rejection in the allografts of bothWT and Vav1AA/AA re-
cipient mice, but enhanced ﬁbrosis present in the Vav1AA/AA allografts
indicates progression to a more chronic stage of rejection compared to
acutely rejected WT allografts (Fig. 6). This is in line with the observed
histological features including acute cellular rejection and interstitial ﬁ-
brosis for Vav1−/−mice with an allograft survival time below 100 days
[23].
Antibody-mediated rejection seems to require Vav1 GEF activity,
as the formation of alloantibodies is almost absent in transplanted
Vav1AA/AA mice (Fig. 5). Antibody levels do not correlate with graft
survival times in individual animals, suggesting that the variations in
graft survival time are caused by different mechanisms. Vav1 has been
implicated in T cell dependent antibody formation, and it would be in-
teresting to see if the GEF function of Vav1 is required for general anti-
body responses [30,31]. Correct migration and localization of activated
T cells to antigenic tissue are essential for developing an immune re-
sponse. Vav1 has been implicated in SDF-1-dependent cell migration,
and has been shown to be important for the retention of T cells at the
sites of inﬂammation [32,33]. Vav1−/− T cells fail to form sustained in-
teractions with local APCs which reduce their ability to initiate a local
immune response. Integrin-mediated adhesion and APC–T cell conju-
gate formation require Vav1 and its GEF activity, whichmay be amech-
anism bywhich Vav1 GEF activity contributes to allograft rejection [20].
Costimulation is an important factor for allogeneic T cell activation,
and blockade of costimulatory pathways has shown promising results
in preventing transplant rejection [5]. Vav1 has been shown to link
CD28 costimulation to T cell activation [34–36]. The GEF function of
Vav1 could contribute to its role downstream of CD28, as Vav1 can en-
hance CD28-induced activation of transcription factors like NFκB via a
Rac-dependent pathway [37]. In addition, CD3/CD28-induced prolifera-
tion and activation of T cells in vitro requires Vav1 GEF activity (Fig. 1)
[20]. However, other costimulatory signals like ICOS, complement or
OX40 contribute to T cell activation during graft rejection [5]. Whether
Vav1 and its GEF function are involved in these different costimulatory
signaling events has not been clariﬁed yet. It is possible that Vav1 trans-
mits different costimulatory signals independently of its GEF activity,
whichmay partially account for the difference in graft survival between
Vav1−/− and Vav1AA/AA mice. Analysis of the effector phenotype of
Vav1AA/AA T cells and their activation in vivo using TCR transgenic
mice could also givemore insights into themechanisms of Vav1 GEF ac-
tivity for allogeneic T cell responses.
5. Conclusion
In conclusion, we have demonstrated that the GEF activity of Vav1
is important for allogeneic T cell activation and proliferation. Disrup-
tion of Vav1 GEF activity in mice led to impaired alloreactivity and
resulted in prolonged cardiac allograft survival. Our results show a
signiﬁcant contribution of Vav1 GEF activity to its role in T cell medi-
ated rejection and indicate a potential novel way to induce immuno-
suppression by targeting Vav1 GEF activity.
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